

8/468/45

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1813nmx
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *
* *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new
names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in
USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI
NEWS 10 Aug 23 In-process records and more frequent updates now in
MEDLINE
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name
change
to PHARMASEARCH
NEWS 14 Oct 09 Korean abstracts now included in Derwent World
Patents
Index
NEWS 15 Oct 09 Number of Derwent World Patents Index updates
increased
NEWS 16 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY
File
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT
NEWS 18 Oct 22 DGENE GETSIM has been improved
NEWS 19 Oct 29 AAASD no longer available

NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *
* *

FILE 'HOME' ENTERED AT 15:53:06 ON 07 NOV 2001

=> file embase medline biosis uspatfull japio wpids caplus agricola
lifesci biotechds jicst-eplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'EMBASE' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 15:53:14 ON 07 NOV 2001

FILE 'BIOSIS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 15:53:14 ON 07 NOV 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 15:53:14 ON 07 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 15:53:14 ON 07 NOV 2001

FILE 'LIFESCI' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 15:53:14 ON 07 NOV 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

=> e engel jurgen/au

E1	1	ENGEL JULIE S/AU
E2	2	ENGEL JUNE/AU

E3	222	-->	ENGEL JURGEN/AU
E4	1		ENGEL JURGN/AU
E5	19		ENGEL JUTTA/AU
E6	449		ENGEL K/AU
E7	11		ENGEL K A/AU
E8	21		ENGEL K C/AU
E9	6		ENGEL K E/AU
E10	2		ENGEL K G/AU
E11	113		ENGEL K H/AU
E12	8		ENGEL K J/AU

=> s e3

L1 222 "ENGEL JURGEN"/AU

=> e wichert burkhard/au

E1	1		WICHERT BOB/AU
E2	1		WICHERT BODO/AU
E3	11	-->	WICHERT BURKHARD/AU
E4	1		WICHERT BURKHARD V/AU
E5	5		WICHERT C/AU
E6	9		WICHERT D/AU
E7	1		WICHERT D M/AU
E8	6		WICHERT E/AU
E9	2		WICHERT E V O N/AU
E10	8		WICHERT EDWARD/AU
E11	5		WICHERT F/AU
E12	2		WICHERT FRIEDEL/AU

=> s e3-e4

L2 12 ("WICHERT BURKHARD"/AU OR "WICHERT BURKHARD V"/AU)

=> e sauerbier dieter/au

E1	14		SAUERBIER D/AU
E2	1		SAUERBIER DIESTER/AU
E3	27	-->	SAUERBIER DIETER/AU
E4	1		SAUERBIER E/AU
E5	1		SAUERBIER F/AU
E6	3		SAUERBIER G A/AU
E7	18		SAUERBIER H/AU
E8	4		SAUERBIER HEINZ/AU
E9	1		SAUERBIER HERBERT/AU
E10	74		SAUERBIER I/AU
E11	15		SAUERBIER INGRID/AU
E12	12		SAUERBIER J/AU

=> s e1-e3

L3 42 ("SAUERBIER D"/AU OR "SAUERBIER DIESTER"/AU OR
"SAUERBIER DIETER
"/AU)

=> e reissman thomas/au

E1	1		REISSMAN T L/AU
E2	1		REISSMAN TH/AU

E3 2 --> REISSMAN THOMAS/AU
 E4 1 REISSMAN THOMAS LINCOLN/AU
 E5 2 REISSMAN Z/AU
 E6 2 REISSMANN A/AU
 E7 9 REISSMANN B/AU
 E8 1 REISSMANN C/AU
 E9 8 REISSMANN C B/AU
 E10 12 REISSMANN CARLOS BRUNO/AU
 E11 23 REISSMANN E/AU
 E12 4 REISSMANN EVA/AU

=> s e1-e4

L4 5 ("REISSMAN T L"/AU OR "REISSMAN TH"/AU OR "REISSMAN THOMAS"/AU
 OR "REISSMAN THOMAS LINCOLN"/AU)

=> s l1-l4

L5 261 (L1 OR L2 OR L3 OR L4)

=> s l5 and cetrorelix

L6 29 L5 AND CETRORELIX

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 22 DUP REM L6 (7 DUPLICATES REMOVED)

=> d bib ab 1-22

L7 ANSWER 1 OF 22 USPATFULL
 AN 2001:173567 USPATFULL
 TI Means for treating prostate hypertrophy and prostate cancer
 IN Engel, Jurgen, Alzenau, Germany, Federal Republic of
 Reissmann, Thomas, Frankfurt am Main, Germany, Federal
 Republic of
 Riethmuller-Winzen, Hilde, Frankfurt am Main, Germany, Federal
 Republic
 of
 Rawert, Jurgen, Alzenau, Germany, Federal Republic of
 PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal
 Republic of
 (non-U.S. corporation)
 PI US 6300313 B1 20011009
 AI US 1999-401851 19990922 (9)
 RLI Division of Ser. No. US 1998-57458, filed on 9 Apr 1998, now
 patented,
 Pat. No. US 5998377
 PRAI US 1996-25990 19960912 (60)
 US 1997-43228 19970410 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Goldberg, Jerome D.
 LREP Pillsbury Winthrop LLP
 CLMN Number of Claims: 5
 ECL Exemplary Claim: 1

DRWN 7 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 258

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A regime for therapeutic management of a benign prostatic hyperplasia

and prostatic cancer employs **Cetrorelix** alone or in combination with .alpha.-reductase inhibitors or

.alpha.-receptor

blocking agents. The regiment reduces the volume of the prostate and

avoids the side effects associated with testosterone levels being in a

castration range. **Cetrorelix** is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per

day to 0.30 mg/kg body weight per week or at levels of about 25 to 120

mg of **Cetrorelix** per month or 0.376 mg/kg to 1.71 mg/kg per month. **Cetrorelix** can be administered with .alpha.-reductase inhibitors or a .alpha.-receptor blocking agents.

L7 ANSWER 2 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 1

AN 2001:192045 BIOSIS

DN PREV200100192045

TI Diagnostic composition containing an LH-RH antagonist for hysteroscopy.

AU Engel, Jurgen (1); Diedrich, Klaus; Felberbaum, Ricardo

CS (1) Alzenau Germany

ASSIGNEE: Asta Medica Aktiengesellschaft, Germany

PI US 6106805 August 22, 2000

SO Official Gazette of the United States Patent and Trademark Office Patents,

(Aug. 22, 2000) Vol. 1237, No. 4, pp. No Pagination. e-file.

ISSN: 0098-1133.

DT Patent

LA English

AB The invention relates to a diagnostic composition for improving the

effectiveness of hysteroscopy, characterized in that it contains an LH-RH

antagonist, in particular **cetrorelix**. The composition is envisaged for use prior to hysteroscopy and/or for preparation for

surgery, specifically in a single dose of between 0.1 and 2 mg/kg.

However, the composition can also be administered, for use prior to

hysteroscopy and/or for preparation for surgery, in a multiple dose of

between 0.01 and 0.5 mg/kg, preferably spread over 1-14 days. The composition is furthermore suitable for use in hysteroscopy in combination

with the subsequent treatment of pathological conditions of the uterus

such as myoma and endometrial hyperplasia.

L7 ANSWER 3 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2

AN 2000:477618 BIOSIS

DN PREV200000477618

TI Process for the preparation of immobilized and activity-stabilized complexes of LHRH antagonists.

AU **Engel, Jurgen** (1); Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter; Naumann, Wolfgang; Murgas, Sandra

CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany

PI US 6054555 April 25, 2000

SO Official Gazette of the United States Patent and Trademark Office Patents,
(Apr. 25, 2000) Vol. 1233, No. 4, pp. No pagination. e-file.
ISSN: 0098-1133.

DT Patent

LA English

AB In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2 O5 in vacuo. If complexes having a defined composition are to be obtained, lyophilization proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L7 ANSWER 4 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 3

AN 2000:484741 BIOSIS

DN PREV200000484741

TI Means for treating prostate hypertrophy and prostate cancer.

AU **Engel, Jurgen** (1); Reissmann, Thomas; Riethmuller-Winzen, Hilde; Rawert, Jurgen

CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Germany

PI US 6054432 April 25, 2000

SO Official Gazette of the United States Patent and Trademark Office Patents,

DT Patent
LA English
AB A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs **Cetrorelix** alone or in combination with alpha-reductase inhibitors or alpha-receptor blocking agents.
The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range **Cetrorelix** is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of **Cetrorelix** per month or 0.376 mg kg to 1.71 mg/kg per month **Cetrorelix** can be administered with alpha-reductase inhibitors or alpha-receptor blocking agents.

L7 ANSWER 5 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 4
AN 2000:355483 BIOSIS
DN PREV200000355483

TI Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation.

AU Engel, Jorgen (1); Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter; Naumann, Wolfgang; Murgas, Sandr

CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany

PI US 6022860 February 08, 2000

SO Official Gazette of the United States Patent and Trademark Office Patents,
(Feb. 8, 2000) Vol. 1231, No. 2, pp. No pagination. e-file.
ISSN: 0098-1133.

DT Patent
LA English

AB In this invention, a release-delaying system is to be developed for LHRH

antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks

by complexation with suitable biophilic carriers. The acidic polyamino

acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the

solutions and precipitation of the complexes, which are subsequently

centrifuged off and dried over P2 O5 in vacuo. If complexes having a

defined composition are to be obtained, lyophilization proves to be a

suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system,

the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the

molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L7 ANSWER 6 OF 22 USPATFULL
AN 2000:70812 USPATFULL
TI Means for treating prostate hypertrophy and prostate cancer
IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of
ReiBsmann, Thomas, Frankfurt am Main, Germany, Federal
Republic of
Riethmuller-Winzen, Hilde, Frankfurt am Main, Germany, Federal
Republic
of
Rawert, Jurgen, Alzenau, Germany, Federal Republic of
PA ASTA Medica AG, Dresden, Germany, Federal Republic of (non-U.S.
corporation)
PI US 6071882 20000606
AI US 1998-62704 19980420 (9)
RLI Division of Ser. No. US 1997-908198, filed on 7 Aug 1997
PRAI US 1996-25990 19960912 (60)
US 1997-43228 19970410 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Goldberg, Jerome D.
LREP Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A regime for therapeutic management of a benign prostatic
hyperplasia
and prostatic cancer employs **Cetrorelix** alone or in
combination with .alpha.-reductase inhibitors or
.alpha.-receptor
blocking agents. The regimen reduces the volume of the
prostate and
avoids the side effects associated with testosterone levels
being in a
castration range. **Cetrorelix** is administered at dosages
between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body
weight per
day to 0.30 mg/kg body weight per week or at levels of about
25 to 120
mg of **Cetrorelix** per month or 0.376 mg/kg to 1.71 mg/kg per
month. **Cetrorelix** can be administered with .alpha.-reductase
inhibitors or .alpha.-receptor blocking agents.

L7 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 2000:725497 CAPLUS
DN 133:261948

TI Method for a programmed controlled ovarian stimulation protocol
 IN Engel, Jorgen; Riethmuller-winzen, Hilde
 PA Asta Medica A.-G., Germany
 SO PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059542	A1	20001012	WO 2000-EP2466	20000321
	W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRAI US 1999-127241 P 19990331
 US 1999-131632 P 19990428

AB A method of therapeutic management of infertility by programming of controlled ovarian stimulation (COS) and assisted reproductive procedures (ART) the improvement consisting of (a) suppression of premature ovulation with an LHRH-antagonist in controlled ovarian stimulation (COS) and assisted reproductive techniques (ART) with multiple follicle and oocyte development; (b) programming the start of controlled ovarian stimulation (COS) by the administration of progestogen only - or alternatively combined oral contraceptive preps.; (c) exogenous stimulation of the ovarian follicle growth; (d) ovulation induction with HCG, native LHRH, LHRH-agonists or recombinant LH; (e) application of assisted reprodn. techniques, esp. of IVF, ICSI, GIFT, ZIFT or by intrauterine insemination by sperm injection.

RE.CNT 6
 RE

- (1) Albano, C; HUMAN REPRODUCTION 1996, V11/10(2114-2118)
- (2) Asta Medica Ag; EP 0788799 A 1997 CAPLUS
- (3) Asta Medica Ag; CA 2200541 A 1998 CAPLUS
- (4) Bouchard, P; OVULATION INDUCTION: UPDATE: THE PROCEEDINGS OF THE WORLD CONGRESS ON OVULATION INDUCTION 1998, P115 CAPLUS
- (5) Felberbaum, R; IN VITRO FERT ASSISTED REPROD, PROC WORLD CONGR 1997, P397 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:894792 CAPLUS
 DN 134:141823

TI New LHRH antagonists with enhanced biological activity:
 Preclinical and
 clinical results
 AU Kutscher, Bernhard; Bernd, Michael; Gunther, Eckhard; Deger,
 Wolfgang;
 Reissmann, Thomas; Beckers, Thomas; Deghenghi, Romano; **Engel,**
Jurgen
 CS Corporate Research, ASTA Medica AG, Frankfurt, D-60314, Germany
 SO Pept. New Millennium, Proc. Am. Pept. Symp., 16th (2000),
 Meeting Date
 1999, 655-657. Editor(s): Fields, Gregg B.; Tam, James P.;
 Barany,
 George. Publisher: Kluwer Academic Publishers, Dordrecht, Neth.
 CODEN: 69ATHX
 DT Conference; General Review
 LA English
 AB A brief review/discussion with 4 refs. on the title topic with
 focus on
Cetrorelix, Antarelix, and D-26344 and their use in treating sex
 hormone-dependent tumors and nonmalignant conditions.
 RE.CNT 4
 RE
 (1) Bernd, M; PCT/DE96/02171
 (2) Deghenghi, R; WO 92/19651 A1 CAPLUS
 (3) Kutscher, B; Angew Chem 1997, V109, P2240
 (4) Muller, A; Int J Peptide Protein Res 1994, V43, P264 MEDLINE

 L7 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:26845 CAPLUS
 DN 132:160805
 TI Disposition and metabolism of **cetrorelix**, a potent luteinizing
 hormone-releasing hormone antagonist, in rats and dogs
 AU Schwahn, Martin; Schupke, Hubert; Gasparic, Antje; Krone,
 Dorothee; Peter,
 Gernot; Hempel, Roland; Kronbach, Thomas; Locher, Mathias; Jahn,
 Wolfgang;
Engel, Jurgen
 CS Corporate Research and Development, ASTA Medica AG,
 Frankfurt/Main,
 D-60314, Germany
 SO Drug Metab. Dispos. (2000), 28(1), 10-20
 CODEN: DMDSAI; ISSN: 0090-9556
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 AB Disposition and metab. of **cetrorelix** was studied in intact and
 bile duct-cannulated rats and dogs after s.c. injection. An
 s.c. dose of
 0.1 mg/kg [¹⁴C]**cetrorelix** was rapidly and completely absorbed in
 rats. Tmax in plasma and most tissues was at 2 h.
 Radioactivity at the
 injection site in rats declined to 10% by 24 h. The extent of
¹⁴C
 absorption in rats calcd. from excretion until 264 h was 94%.
 Exposure of
 the target organ pituitary gland was demonstrated with a time
 course
 similar to plasma but on a higher level. Rats excreted 69.6% of
 radioactivity via feces and 24.3% into urine. Excretion was
 nearly

complete within 48 h. No enteral resorption was detected. In dogs tmax in plasma was 1.3 h. 14C- and **cetrorelix** plasma levels were similar until 24 h, indicating a negligible amt. of metabolites. A dose of 1 mg/kg in dogs showed an increasing influence of a slow absorption phase (flip-flop). In dogs equal amts. of the 14C dose were found within 192 h in feces and urine, 46 and 48%, resp. In urine of both species, only intact **cetrorelix** was detected. In bile and feces of both species qual. the same metabolites were found, characterized as truncated peptides of the parent decapeptide. The major metabolite occurring in bile of both species was the (1-7)heptapeptide. The amts. of the (1-4)tetrapeptide in feces of rats but not in that of dogs increase with time, suggesting addnl. degrdn. of the peptide in the gastrointestinal tract of rats by enteric metabolization.

RE.CNT 24

RE

- (2) Bajusz, S; Proc Natl Acad Sci USA 1988, V85, P1637 CAPLUS
(5) Berger, H; Drug Metab Dispos 1993, V21, P818 CAPLUS
(6) Berger, H; Regul Pept 1991, V33, P299 CAPLUS
(7) Chan, R; Biochem Biophys Res Commun 1985, V127, P673 CAPLUS
(8) Chan, R; Drug Metab Dispos 1991, V19, P858 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 22 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 5
AN 2000:292181 BIOSIS
DN PREV200000292181
TI Means for treating prostate cancer.
AU **Engel, Jorgen**; Reissmann, Thomas (1); Riethmuller-Winzen, Hilde;
Rawert, Jorgen
CS (1) Frankfurt/Main Germany
ASSIGNEE: ASTA Medica Aktiengesellschaft
PI US 5998377 December 07, 1999
SO Official Gazette of the United States Patent and Trademark
Office Patents,
(Dec. 7, 1999) Vol. 1229, No. 1, pp. No pagination. e-file..
ISSN: 0098-1133.
DT Patent
LA English
AB A regime for therapeutic management of a benign prostatic
hyperplasia and
prostatic cancer employs **Cetrorelix** alone or in combination with
alpha-reductase inhibitors or alpha-receptor blocking agents.
The regimen
reduces the volume of the prostate and avoids the side effects
associated
with testosterone levels being in a castration range. **Cetrorelix**
is administered at dosages between 0,5 mg/day and 20 mg/week or
about
0.014 mg/kg body weight per day to 0,30 mg/kg body weight per
week or at
levels of about 25 to 120 mg of **Cetrorelix** per month or 0.376

mg/kg to 1.71 mg/kg per month. **Cetrorelix** can be administered with alpha-reductase inhibitors or alpha-receptor blocking agents.

L7 ANSWER 11 OF 22 USPATFULL

AN 1999:146533 USPATFULL

TI Nova- and decapeptides in the preparation of a drug for the treatment of
aids

IN **Engel, Jurgen**, Alzenau, Germany, Federal Republic of
Kutscher, Bernhard, Maintal, Germany, Federal Republic of
Bernd, Michael, Frankfurt am Main, Germany, Federal Republic of
Niemeyer, Ulf, Offenbach, Germany, Federal Republic of

PA ASTA Medica AG, Germany, Federal Republic of (non-U.S.
corporation)

PI US 5985834 19991116

WO 9500168 19950105

AI US 1995-569111 19951218 (8)

WO 1994-EP1037 19940402

19951218 PCT 371 date

19951218 PCT 102(e) date

PRAI DE 1993-4320201 19930618

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilla J.; Assistant Examiner:
Delacroix-Muirheid, C.

LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro

LLP

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described are LHRH-antagonistic and bombesin-antagonistic
nona- and

decapeptides suitable for use in the preparation of a drug for
the

treatment of AIDS and ARC as well as for use in the
preparation of an

immunostimulation drug.

L7 ANSWER 12 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-542841 [46] WPIDS

CR 1994-265229 [33]

DNC C1999-158621

TI Treatment of female infertility, especially by in-vitro
fertilization.

DC B04

IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B

PA (ASTA) ASTA MEDICA AG

CYC 17

PI EP 947200 A2 19991006 (199946)* DE 5p

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

ADT EP 947200 A2 Div ex EP 1994-101672 19940204, EP 1999-102340
19940204

FDT EP 947200 A2 Div ex EP 611572

PRAI DE 1993-4305225 19930219

AB EP 947200 A UPAB: 19991110

NOVELTY - Sterile freeze-dried **cetrorelix** acetate (a peptide

described in EP299402) is used in the treatment of female infertility.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the

following: (1) use of sterile freeze-dried **cetrorelix** acetate for protecting gonads against noxious agents that damage germ cells, e.g.

radiation treatment and chemotherapy; (2) a composition comprising sterile

freeze-dried **cetrorelix** acetate and optionally excipients for use in the treatment of female infertility; (3) a composition comprising

sterile freeze-dried **cetrorelix** acetate and optionally excipients for protecting gonads against noxious agents that damage germ

cells, e.g. radiation treatment and chemotherapy with cytostatic agents.

ACTIVITY - None given.

MECHANISM OF ACTION - Luteinizing hormone-releasing hormone (LHRH)

antagonist.

USE - In an in-vitro fertilization procedure in which **cetrorelix** is administered to control the time of ovulation during

an ovary stimulation treatment by preventing a pre-ovulation increase in

luteinizing hormone (LH) levels, whereupon exogenous gonadotropin is

administered to induce ovulation after follicle maturation.

Dwg.0/0

L7 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2001 ACS

AN 1999:708625 CAPLUS

DN 131:295922

TI Method for the treatment of fertility disorders using an LHRH antagonist

to partially suppress endogenous gonadotropins during intrauterine insemination

IN **Engel, Jorgen**; Riethmuller-Winzen, Hilde; Reissmann, Thomas

PA Asta Medica Aktiengesellschaft, Germany

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9955357	A1	19991104	WO 1999-EP2133	19990329
	W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9937028	A1	19991116	AU 1999-37028	19990329
	BR 9909802	A	20001226	BR 1999-9802	19990329

EP 1082129 A1 20010314 EP 1999-919152 19990329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,

IE, SI, LT, LV, FI, RO
NO 2000005145 A 20001013 NO 2000-5145 20001013
PRAI US 1998-82743 P 19980423
WO 1999-EP2133 W 19990329

AB In the method of therapeutic management of infertility by
intrauterine
insemination the improvement consisting of (a) the dose-dependent
suppression of endogenous gonadotropins, esp. LH, with a LH-RH
Antagonist
allowing the maintenance of physiol. estrogen levels, (b)
exogenous
stimulation of the ovarian follicle growth, (c) ovulation
induction with
HCG, native LHRH, LHRH-Agonists or recombinant LH, (d)
intrauterine
insemination by sperm injection. The LHRH Antagonists may be
preferably
Cetrorelix or Antarelix. The stimulation is performed by
administration of HMG or recombinant FSH with or without
recombinant LH or
with antiestrogens as for example Clomiphene as well as with the
combination of antiestrogens as for example Clomiphene with
gonadotropins.

RE.CNT 5

RE

- (1) Asta Medica AG; EP 0611572 A 1994 CAPLUS
- (2) Asta Medica AG; EP 0788799 A 1997 CAPLUS
- (3) Bouchard, P; Ovul Ind Update '98, Proc World Conf, 2nd 1998, P115
CAPLUS
- (4) Crowley, W; US 5130137 A 1992 CAPLUS
- (5) Schering AG; DE 19604231 A 1997 CAPLUS

L7 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2001 ACS

AN 2000:739102 CAPLUS

DN 134:275789

TI Development of the LH-RH antagonist **Cetrorelix** for tumor therapy

AU Perrissoud, Daniel; Reissmann, Thomas; **Engel, Jurgen**

CS Corporate Research & Development ASTA Medica, Frankfurt,
D-60314, Germany

SO Actual. Chim. Ther. (1999), 25, 243-249

CODEN: ACHTD9; ISSN: 0338-8999

PB Editions Scientifiques et Medicales Elsevier

DT Journal; General Review

LA English

AB A review with 10 refs. The availability of the LH-releasing
hormone-antagonist **Cetrorelix** for clin. use opens up new
therapeutic modalities of diseases dependent on sex hormones.

RE.CNT 10

RE

- (1) Bajusz, S; Proc Natl Acad Sci 1988, V85, P1637 CAPLUS
- (2) Behre, H; Exp and Clin Endocrinol 1994, V40, P241 CAPLUS
- (6) Matsuo, H; Biochem Biophys Res Commun 1971, V43, P1334 CAPLUS
- (7) Reissmann, T; Eur J Cancer 1996, V32A, P1574 CAPLUS
- (8) Reissmann, T; Hum Reprod 1995, V10, P1974 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 22 USPATFULL DUBLICATE 6
 AN 1998:75185 USPATFULL
 TI Long-acting injection suspensions and a process for their
 preparation
 IN **Engel, Jorgen**, Alzenau, Germany, Federal Republic of
 Klokke-Bethke, Karin, Lenggries, Germany, Federal Republic of
Reissman, Thomas, Frankfurt, Germany, Federal Republic of
 Hilgard, Peter, Frankfurt, Germany, Federal Republic of
 PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal
 Republic of
 (non-U.S. corporation)
 PI US 5773032 19980630
 AI US 1996-661017 19960610 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Azpuru, Carlos A.
 LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro
 LLP
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 373
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Poorly soluble salts of LHRH analogues, for example **cetorelix**
 embonate, display an intrinsic sustained release effect in the
 grain
 size 5 .mu.m to 200 .mu.m.

L7 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:180776 CAPLUS
 DN 128:226267
 TI Means for treating prostate hypertrophy and prostate cancer with
Cetorelix, alone or in combination with other agents
 IN **Engel, Jorgen**; Reissmann, Thomas; Riethmuller-Winzen, Hilde;
 Rawert, Jorgen
 PA Asta Medica A.-G., Germany
 SO PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9810781	A1	19980319	WO 1997-EP4740	19970901
W: AU, BR, CN, CZ, EE, HU, IL, IS, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6054432	A	20000425	US 1997-908198	19970807
AU 9746198	A1	19980402	AU 1997-46198	19970901
EP 925069	A1	19990630	EP 1997-944818	19970901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1230121	A	19990929	CN 1997-197904	19970901
BR 9713197	A	20000404	BR 1997-13197	19970901
JP 2001500500	T2	20010116	JP 1998-513204	19970901
CA 2215015	AA	19980312	CA 1997-2215015	19970910

	US 5998377	A	19991207	US 1998-57458	19980409
	US 6071882	A	20000606	US 1998-62704	19980420
	NO 9901192	A	19990428	NO 1999-1192	19990311
	US 6300313	B1	20011009	US 1999-401851	19990922
PRAI	US 1996-25990	P	19960912		
	US 1997-43228	P	19970410		
	US 1997-908198	A3	19970807		
	WO 1997-EP4740	W	19970901		
	US 1998-57458	A3	19980409		

AB A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs **Cetrorelix** alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the vol. of the prostate and avoids the side effects assocd. with testosterone levels being in a castration range. **Cetrorelix** is administered at dosages between 0.5 mg/day and 20 mg/wk or about 0.014 mg/kg body wt. per day to 0.30 mg/kg body wt. per wk or at levels of about 25 to 120 mg of **Cetrorelix** per mo or 0.376 mg/kg to 1.71 mg/kg per mo. **Cetrorelix** can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.

L7 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2001 ACS
 AN 1999:538778 CAPLUS
 DN 131:139954
 TI LHRH antagonists in the treatment of fertility disorders
 IN Bouchard, Philippe; Frydman, Rene; Diedrich, Klaus; Engel, Jurgen ; Devroey, Paul
 PA Asta Medica AG, Germany
 SO Can. Pat. Appl., 15 pp.
 CODEN: CPXXEB

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	CA 2200541	AA	19980722	CA 1997-2200541	19970320
PRAI	US 1997-786937		19970122		

AB A method of treating infertility disorders by administering an LH-RH

antagonist, preferably **Cetrorelix**, in amts. to selectively suppress endogenous LH but not FSH secretion and inducing follicle growth by administration of exogenous gonadotropin. The selective suppression of LH allows FSH secretion to be at natural levels thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual s.c. dose in the range of 1 mg to 10 mg, preferably 2 mg - 6 mg. In multiple dosing posol., LH-RH antagonist can be administered s.c. in an amt. in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day

4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addn. rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the neg. effects of HCG.

L7 ANSWER 18 OF 22 USPATFULL

AN 97:78416 USPATFULL

TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases

IN **Engel, Jorgen**, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of

(non-U.S. corporation)

PI US 5663145 19970902

AI US 1994-354838 19941208 (8)

PRAI DE 1993-4342091 19931209

DT Utility

FS Granted

EXNAM Primary Examiner: Russel, Jeffrey E.

LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 7

DRWN No Drawings

LN.CNT 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB For application during the treatment of benign and malign tumour

diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L7 ANSWER 19 OF 22 USPATFULL

AN 95:43015 USPATFULL

TI Compressed gas packages using polyoxyethylene glyceryl oleates

IN **Hettche, Helmut**, Dietzenbach, Germany, Federal Republic of

Engel, Jorgen, Alzenau, Germany, Federal Republic of

Muckenschnabel, Reinhard, Frankfurt, Germany, Federal Republic

of

PA Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of

(non-U.S. corporation)

PI US 5415853 19950516

AI US 1993-33789 19930317 (8)

PRAI DE 1992-42085055 19920317

DE 1992-42151880 19920508

DE 1992-42308763 19920916
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner:
Benston, Jr.,
William E.
LREP Cushman Darby & Cushman
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aerosol compressed gas packages containing a member of the
group
consisting of polyoxyethylene-25-glyceryl trioleate,
polyoxyethylene-30-glyceryl monooleate and
polyoxyethylene-20-glyceryl
monooleate as suspension stabilizer and/or valve lubricant.
These
materials are especially useful when the package contains TG
227 or TG
134a as the propellant.

L7 ANSWER 20 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
DUPLICATE

7
AN 1994-265229 [33] WPIDS
DNC C1994-121294
TI Freeze-dried peptide compsns. - prepd. by freeze drying soln. of
peptide
in aq. acetic acid.
DC B04
IN ENGEL, J; REISSMANN, T; SAUERBIER, D; WICHERT, B; BURKHARD, W;
JUERGEN, E
PA (ASTA) ASTA MEDICA AG
CYC 32
PI EP 611572 A2 19940824 (199433)* DE 5p
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DE 4305225 A1 19940825 (199433) 5p
AU 9455235 A 19940825 (199436)
NO 9400564 A 19940822 (199436)
CA 2115943 A 19940820 (199439)
CZ 9400312 A3 19940914 (199439)
BR 9400617 A 19940927 (199440)
SK 9400195 A3 19940907 (199440)
FI 9400779 A 19940820 (199441)
JP 06271476 A 19940927 (199443) 5p
ZA 9401136 A 19941026 (199444) 12p
HU 67117 T 19950228 (199514)
EP 611572 A3 19950111 (199538)
AU 671881 B 19960912 (199644)
CN 1112019 A 19951122 (199737)
SG 46632 A1 19980220 (199822)
BR 1101004 A3 19980512 (199828)
CZ 284314 B6 19981014 (199847)
NZ 314707 A 19990225 (199914)
CZ 285768 B6 19991117 (200002)
EP 611572 B1 20000607 (200032) DE
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE 59409389 G 20000713 (200037)
 HU 218281 B 20000728 (200045)
 RU 2145234 C1 20000210 (200048)
 ES 2148247 T3 20001016 (200058)
 TW 387812 A 20000421 (200061)
 ADT EP 611572 A2 EP 1994-101672 19940204; DE 4305225 A1 DE
 1993-4305225
 19930219; AU 9455235 A AU 1994-55235 19940217; NO 9400564 A NO
 1994-564
 19940218; CA 2115943 A CA 1994-2115943 19940218; CZ 9400312 A3
 CZ 1994-312
 19940214; BR 9400617 A BR 1994-617 19940218; SK 9400195 A3 SK
 1994-195
 19940218; FI 9400779 A FI 1994-779 19940218; JP 06271476 A JP
 1994-20532
 19940217; ZA 9401136 A ZA 1994-1136 19940218; HU 67117 T HU
 1994-481
 19940218; EP 611572 A3 EP 1994-101672 19940204; AU 671881 B AU
 1994-55235
 19940217; CN 1112019 A CN 1994-101378 19940218; SG 46632 A1 SG
 1996-6874
 19940204; BR 1101004 A3 BR 1997-1101004 19970514; CZ 284314 B6
 CZ 1994-312
 19940214; NZ 314707 A Div ex NZ 1994-250906 19940217, NZ
 1994-314707
 19940217; CZ 285768 B6 CZ 1998-974 19940214; EP 611572 B1 EP
 1994-101672
 19940204, Related to EP 1999-102340 19940204; DE 59409389 G DE
 1994-509389
 19940204, EP 1994-101672 19940204; HU 218281 B HU 1994-481
 19940218; RU
 2145234 C1 RU 1994-5001 19940218; ES 2148247 T3 EP 1994-101672
 19940204;
 TW 387812 A TW 1994-100769 19940131
 FDT AU 671881 B Previous Publ. AU 9455235; CZ 284314 B6 Previous
 Publ. CZ
 9400312; NZ 314707 A Div ex NZ 250906; CZ 285768 B6 Previous
 Publ. CZ
 9800974; EP 611572 B1 Related to EP 947200; DE 59409389 G Based
 on EP
 611572; HU 218281 B Previous Publ. HU 67117; ES 2148247 T3 Based
 on EP
 611572
 PRAI DE 1993-4305225 19930219
 AB EP 611572 A UPAB: 19991110
 Freeze-dried compsns. comprising a peptide of 3-15 amino acid
 units and
 opt. one or more matrix materials are characterised in that 1
 pt. wt. of
 the peptide is dissolved in 100-10,000 pts. wt. of acetic acid
 and then
 transferred to water and the resulting soln. is freeze dried.
 USE/ADVANTAGE - The compsns. esp. contain **cetrorelix** (EP
 299402), which is used in the treatment of female infertility
 (for
 controlling ovulation prior to isolating egg cells for in-vitro
 fertilisation) and for gonad protection in male patients (e.g.
 undergoing
 ratio- or chemotherapy). The aq. acetic acid soln. can be
 sterilised by

filtration without gelation or hydrolysis of the peptide.
Dwg.0/0

L7 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1996:316833 CAPLUS
DN 125:722
TI Persistent blockade of the pituitary gonadal axis in patients
with
prostatic cancer by the LH-RH antagonist SB-75 (**Cetrorelix**)
AU Gonzalez-Barcena, D.; Vadillo-Buenfil, M.; Cortez-Morales, A.;
Romero, M.
A.; Engel, J.; Comaru-Schally, A. M.; Schally, A. V.; **Reissman,**
Th.
CS Hosp. Esp. C.M.R., IMSS, Mexico City, Mex.
SO Proc. Int. Cancer Congr., Free Pap. Posters, 16th (1994), Volume
3,
2201-2204. Editor(s): Rao, R. S. Publisher: Monduzzi Editore,
Bologna,
Italy.
CODEN: 62UYAO
DT Conference
LA English
AB Our objective was to use the LH-RH analog SB-75, **Cetrorelix** to
treat a group of patients with advanced prostrate carcinoma. The
antagonists SB-75 was well tolerated. No local or systemic
effects were
obsd. These results show that the chronic administration of the
LH-RH
antagonists SB-75, **Cetrorelix** is an effective therapy for the
management of advanced prostate cancer.

L7 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2001 ACS
AN 1995:228423 CAPLUS
DN 122:106501
TI Synthesis of [U-14C]Arg labeled decapeptide **cetrorelix**, a novel
luteinizing hormone-releasing hormone antagonist
AU Locher, Mathias; Johnston, James; Muller, Thomas; Borbe, Harald
O.;
Kutscher, Bernhard; **Engel, Jurgen**
CS ASTA Medica AG, Frankfurt, D-60001, Germany
SO J. Labelled Compd. Radiopharm. (1994), 34(11), 1091-8
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English
AB The decapeptide **cetrorelix** is a novel LH-releasing hormone
(LH-RH) antagonist. For nonclin. studies concerning absorption,
distribution, metab. and excretion (ADME) in animals the
[14C]-labeled
compd. is essential. Therefore, [U-14C]Arg **cetrorelix** acetate
salt was synthesized by Amersham international, Buckinghamshire
(England)
from precursor peptides provided by Degussa AG, Hanau-Wolfgang
(Germany).
[U-14C]Arg labeled **cetrorelix** peptide base has a specific
activity of 8.13 MBq/mg (220 .mu.Ci/mg) and a mol. wt. of 1442.6
g/mol at
this specific activity. The chem. and radiochem. purity (92.2%
decapeptide content and 97.6%, resp.) detd. by HPLC is suitable
for

nonclin. investigations.

=> e wolf ingrid/au

E1 1 WOLF INGETRAUT/AU
E2 15 WOLF INGO/AU
E3 40 --> WOLF INGRID/AU
E4 1 WOLF INGRID DE/AU
E5 3 WOLF INGRID H/AU
E6 1 WOLF IRENE/AU
E7 1 WOLF IRIS/AU
E8 3 WOLF IRMA/AU
E9 8 WOLF IRMELIN/AU
E10 4 WOLF IRVING/AU
E11 17 WOLF IRVING W/AU
E12 2 WOLF IRVING WILLIAM/AU

=> s e3-e5

L8 44 ("WOLF INGRID"/AU OR "WOLF INGRID DE"/AU OR "WOLF
INGRID H"/AU)

=> s l8 and cetrorelix

L9 0 L8 AND CETRORELIX

=> s l8 and lyophiliz?

L10 6 L8 AND LYOPHILIZ?

=> dup rem l10

PROCESSING COMPLETED FOR L10

L11 6 DUP REM L10 (0 DUPLICATES REMOVED)

=> d bib ab 1-6

L11 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS

AN 1992:46317 CAPLUS

DN 116:46317

TI Preparation of a stable parenteral immunostimulant composition
containing

splenopentin

IN **Wolf, Ingrid**

PA Berlin-Chemie A.-G., Germany

SO Ger. (East), 3 pp.

CODEN: GEXXA8

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 292382	A5	19910801	DD 1990-338431	19900306
	DD 292382	B5	19940324		
	EP 445581	A1	19910911	EP 1991-102431	19910220
	EP 445581	B1	19930505		

R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE

AT 88903	E	19930515	AT 1991-102431	19910220
ES 2055469	T3	19940816	ES 1991-102431	19910220
CA 2037531	AA	19910907	CA 1991-2037531	19910304
JP 04211611	A2	19920803	JP 1991-38808	19910305
JP 06092315	B4	19941116		
PRAI DD 1990-338431		19900306		
EP 1991-102431		19910220		

AB A stable, liq. or **lyophilized** immunostimulant prepn. for parenteral administration to humans contains splenopentin or its analogs combined with a hydroxybenzoic acid ester as stabilizer. Thus, 27 g diacetylsplenopentin-HCl was dissolved in 600 mL 0.02M H3PO4; the pH was adjusted to 8.0-9.0 with NaOH and then adjusted after 20 min to 7.5. Me hydroxybenzoate 1.5 g was dissolved in 300 mL water at 90-95.degree. and added to the above soln.; the pH was adjusted to 6.9-7.1 and the soln. was sterilized by filtration.

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1989:463948 CAPLUS
DN 111:63948
TI Sustained-release pharmaceuticals containing peptide-sulfonated polystyrene complexes
IN Fechner, Klaus; Bienert, Michael; Klauschenz, Erhard; **Wolf, Ingrid**; Mehliis, Burkhard; Loth, Fritz; Dautzenberg, Horst; Bergfeld, Jost
PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SO Ger. (East), 4 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DD 256605	A3	19880518	DD 1982-246469	19821223

AB Sustained-release pharmaceuticals contain complexes of biol. active peptides, polypeptides, or their derivs. or salts, with sulfonated polystyrene or its salts. Polystyrene (mol. wt. 200,000) was sulfonated and neutralized with NaOH to give a polymer with a degree of substitution of 1. A **lyophilizate** contg. 2.5 mg angiotensin and 25 mg sorbitol was dissolved in a soln. contg. 0.125% Na polystyrenesulfonate and isotonic NaCl to give an injection.

L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations
IN **Wolf, Ingrid**; Schneider, Anita; Tschauschew, Peter
PA Ger. Dem. Rep.

SO Ger. (East), 5 pp.

CODEN: GEXXA8

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 141996	Z	19800604	DD 1979-211139	19790221
AB	A stable LH-RH [9034-40-6] prepn. is made by buffering an aq. soln. of LH-RH to pH 3.5-6.5 and lyophilizing . For example, 4.5 g LH-RH, to 2 g citric acid [77-92-9] and 20 g mannitol (carrier) were dissolved in 900 mL H2O for injection, dild. to 1 L, and adjusted to pH 3.5-4.5 with 1N NaOH. The soln. was sterilized by filtration, divided into 1 mL aliquots, and lyophilized .				

L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS

AN 1980:169260 CAPLUS

DN 92:169260

TI Lyophilized hypotensive preparation for parenteral application

IN Wolf, Ingrid; Klehr, Gabriele

PA Ger. Dem. Rep.

SO Ger. (East), 6 pp.

CODEN: GEXXA8

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 138406	Z	19791031	DD 1978-207389	19780821
	DD 138406	B1	19860507		
AB	A pharmaceutical prepn. of di-Na pentacyanonitrosylferrate (I) [14402-89-2], stable for several y and suitable for parenteral application, with I contg. 5-50 mg-% K, was prepd. by adding an acidic or neutral amino acid or a Na salt of a weak acid and(or) mannitol and lyophilizing the soln. Thus, 50 g I contg. 5 mg-% K was dissolved with 20 g mannitol [69-65-8] in 1 L freshly-distd. H2O and the soln. sterile-filtered, aseptically filled into 1 mL brown glass ampuls, and lyophilized .				

L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS

AN 1975:484842 CAPLUS

DN 83:84842

TI **Lyophilized** gastrin preparations

IN Wolf, Ingrid

PA E. Ger.

SO Ger. (East), 6 pp.

CODEN: GEXXA8

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 109512	Z	19741112	DD 1974-176286	19740131
AB	A parenteral applicable gastrin [9002-76-0] prepn. which is stable at room temp. is prepd. by adding trometamol [77-86-1] to a gastrin soln. and lyophilization. A soln. of the lyophilized gastrin is made immediately before application.				

L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS
 AN 1974:137186 CAPLUS
 DN 80:137186
 TI Parenterally applicable angiotensin preparation with depot action
 IN Matthias, Dietrich; Baumann, Hannelore; Engler, Eberhard; Wolf, Ingrid
 SO Ger. (East), 2 pp.
 CODEN: GEXXA8
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 98610	Z	19730712	DD 1972-163087	19720515
AB	A title prepn. is made by dissolving 2.5 mg lyophilized angiotensin (I) in 1.1-1.5 ml aq. 10-50% soln. of poly(vinylpyrrolidinone) (mol. wt. 25,000-35,000), or as tablets, by mixing I with 2 g lactose or NaCl + 2% talc to yield 2.5-50 mg implants contg. 1.0-5.5 mg I. Both prepn. caused a rise in blood pressure of rats.				

=> d his

(FILE 'HOME' ENTERED AT 15:53:06 ON 07 NOV 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA, LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 15:53:14 ON 07 NOV 2001

	E ENGEL JURGEN/AU
L1	222 S E3
	E WICHERT BURKHARD/AU
L2	12 S E3-E4
	E SAUERBIER DIETER/AU
L3	42 S E1-E3
	E REISSMAN THOMAS/AU
L4	5 S E1-E4
L5	261 S L1-L4
L6	29 S L5 AND CETRORELIX
L7	22 DUP REM L6 (7 DUPLICATES REMOVED)
	E WOLF INGRID/AU
L8	44 S E3-E5
L9	0 S L8 AND CETRORELIX
L10	6 S L8 AND LYOPHILIZ?
L11	6 DUP REM L10 (0 DUPLICATES REMOVED)

=> s l8 and lyophili?

L12 6 L8 AND LYOPHILI?

=> d bib 1-6

L12 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1992:46317 CAPLUS
DN 116:46317
TI Preparation of a stable parenteral immunostimulant composition
containing
splenopentin
IN **Wolf, Ingrid**
PA Berlin-Chemie A.-G., Germany
SO Ger. (East), 3 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 292382	A5	19910801	DD 1990-338431	19900306
	DD 292382	B5	19940324		
	EP 445581	A1	19910911	EP 1991-102431	19910220
	EP 445581	B1	19930505		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	AT 88903	E	19930515	AT 1991-102431	19910220
	ES 2055469	T3	19940816	ES 1991-102431	19910220
	CA 2037531	AA	19910907	CA 1991-2037531	19910304
	JP 04211611	A2	19920803	JP 1991-38808	19910305
	JP 06092315	B4	19941116		
PRAI	DD 1990-338431		19900306		
	EP 1991-102431		19910220		

L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1989:463948 CAPLUS
DN 111:63948
TI Sustained-release pharmaceuticals containing peptide-sulfonated
polystyrene complexes
IN Fechner, Klaus; Bienert, Michael; Klauschenz, Erhard; **Wolf,**
Ingrid
; Mehliis, Burkhard; Loth, Fritz; Dautzenberg, Horst; Bergfeld,
Jost
PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
SO Ger. (East), 4 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 256605	A3	19880518	DD 1982-246469	19821223

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations

IN Wolf, Ingrid; Schneider, Anita; Tschauschew, Peter
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 141996	Z	19800604	DD 1979-211139	19790221

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1980:169260 CAPLUS
DN 92:169260
TI **Lyophilized** hypotensive preparation for parenteral application
IN Wolf, Ingrid; Klehr, Gabriele
PA Ger. Dem. Rep.
SO Ger. (East), 6 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 138406	Z	19791031	DD 1978-207389	19780821
	DD 138406	B1	19860507		

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1975:484842 CAPLUS
DN 83:84842
TI **Lyophilized** gastrin preparations
IN Wolf, Ingrid
PA E. Ger.
SO Ger. (East), 6 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 109512	Z	19741112	DD 1974-176286	19740131

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1974:137186 CAPLUS
DN 80:137186
TI Parenterally applicable angiotensin preparation with depot action
IN Matthias, Dietrich; Baumann, Hannelore; Engler, Eberhard; Wolf, Ingrid
SO Ger. (East), 2 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 98610	Z	19730712	DD 1972-163087	19720515

=> d clm 3

'CLM' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSTR ----- First HIT RN, its text modification, its CA index name,
and
its structure diagram
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it
occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, KWIC, and OCC) may be used with DISPLAY ACC to view a

specified Accession Number.
ENTER DISPLAY FORMAT (BIB):.

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI **Lyophilized** LHRH preparations
IN **Wolf, Ingrid; Schneider, Anita; Tschaushev, Peter**
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 141996	Z	19800604	DD 1979-211139	19790221

=> e schneider anita/au

E1	8	SCHNEIDER ANGELA/AU
E2	10	SCHNEIDER ANGELIKA/AU
E3	1 -->	SCHNEIDER ANITA/AU
E4	3	SCHNEIDER ANITA M H/AU
E5	11	SCHNEIDER ANJA/AU
E6	8	SCHNEIDER ANKE/AU
E7	1	SCHNEIDER ANN/AU
E8	3	SCHNEIDER ANN T/AU
E9	2	SCHNEIDER ANNA/AU
E10	2	SCHNEIDER ANNA M/AU
E11	14	SCHNEIDER ANNE/AU
E12	5	SCHNEIDER ANNE MARIE/AU

=> s e3-e4

L13 4 ("SCHNEIDER ANITA"/AU OR "SCHNEIDER ANITA M H"/AU)

=> d bib ab 1-4

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1981:127390 CAPLUS
DN 94:127390
TI Lyophilized LHRH preparations
IN **Wolf, Ingrid; Schneider, Anita; Tschaushev, Peter**
PA Ger. Dem. Rep.
SO Ger. (East), 5 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 141996	Z	19800604	DD 1979-211139	19790221
AB	A stable LH-RH [9034-40-6] prepn. is made by buffering an aq. soln. of LH-RH to pH 3.5-6.5 and lyophilizing. For example, 4.5 g LH-RH, to 2 g				

citric acid [77-92-9] and 20 g mannitol (carrier) were dissolved in 900 mL H₂O for injection, dild. to 1 L, and adjusted to pH 3.5-4.5 with 1N NaOH. The soln. was sterilized by filtration, divided into 1 mL aliquots, and lyophilized.

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1975:507670 CAPLUS
DN 83:107670
TI Standardization of potassium permanganate solutions by titration with sodium oxalate in the presence of perchloric acid and manganese(II) sulfate
AU Ohlweiler, Otto A.; **Schneider, Anita M. H.**
CS Inst. Quim., Univ. Fed. Rio Grande Sul, Porto Alegre, Brazil
SO An. Assoc. Bras. Quim. (1972), 28(1-2), 23-9
CODEN: AABQAL
DT Journal
LA Portuguese
AB Substituting HClO₄ for H₂SO₄ in the standardization of 0.1N KMnO₄ by direct titrn. of Na₂C₂O₄ in the presence of MnSO₄ permits the titrn. at any temp. between 25.degree. and 80.degree.. The HClO₄ concn. is maintained >2N. The KMnO₄ soln. can be added at rates .1toreq.12 ml/min.

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1972:121112 CAPLUS
DN 76:121112
TI Standardization of potassium permanganate by titration of sodium oxalate in presence of perchloric acid and manganese(II) sulfate
AU Ohlweiler, O. A.; **Schneider, Anita M. H.**
CS Inst. Quim., Univ. Fed., Porto Alegre, Brazil
SO Anal. Chim. Acta (1972), 58(2), 477-80
CODEN: ACACAM
DT Journal
LA English
AB KMnO₄ (0.1 N) was standardized with 0.24 or 0.26 parts/103 std. deviation by titrating 0.08-0.09N Na₂C₂O₄, in the presence of HClO₄ and MnSO₄ catalyst, with the KMnO₄ soln. at 25.degree. or 60.degree., resp.

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1970:50566 CAPLUS
DN 72:50566
TI Colorimetric determination of cobalt with phthalocyanine
AU Meditsch, Jorge de Oliveira; **Schneider, Anita M. H.**
CS Univ. Rio Grande do Sul, Rio Grande do Sul, Brazil
SO Rev. Quim. Ind. (Rio de Janeiro) (1969), 38(446), 16-18
CODEN: RQIRAI
DT Journal
LA Portuguese
AB Heat 200 mg of flux (phthalic anhydride 14.8, urea 6, and boric acid 0.1 g

) with the Co++ soln. at 160-5.degree.C for 5 min and ext. the Co complex
 formed with acetone. After making up to vol. measure the absorbance at
 622 m.mu. Co++ can be detd. in the 2.5-20 ppm range. The av. relative
 error is 5%. Fe++ and Cu++ interfere, .ltoreq.100 ppm of Ni++ can be
 tolerated, while Ca++, Ba++, Sr++, Mg++, Zn++, Cd++, Hg++, and Mn++ do not
 interfere.

=> e tschaushev peter/au

E1	1	TSCHAUSCHE S J/AU
E2	14	TSCHAUSCHEV P/AU
E3	4 -->	TSCHAUSCHEV PETER/AU
E4	1	TSCHAUSHEV G/AU
E5	1	TSCHAUSHEV P/AU
E6	4	TSCHAUT R J/AU
E7	3	TSCHAUTSCHEV P/AU
E8	3	TSCHAWDAROVA R/AU
E9	2	TSCHAWDAROWA M/AU
E10	2	TSCHAWOW A/AU
E11	1	TSCHAWOW ANTOANETA/AU
E12	4	TSCHAWRAKOW G/AU

=> s e2-e5

L14 20 ("TSCHAUSCHEV P"/AU OR "TSCHAUSCHEV PETER"/AU OR
 "TSCHAUSHEV G"/AU OR "TSCHAUSHEV P"/AU)

=> s l14 and lyophili?

L15 1 L14 AND LYOPHILI?

=> d bib ab

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 1981:127390 CAPLUS

DN 94:127390

TI **Lyophilized** LHRH preparations

IN Wolf, Ingrid; Schneider, Anita; **Tschaushev, Peter**

PA Ger. Dem. Rep.

SO Ger. (East), 5 pp.

CODEN: GEXXA8

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DD 141996	Z	19800604	DD 1979-211139	19790221
AB	A stable LH-RH [9034-40-6] prepn. is made by buffering an aq. soln. of				

LH-RH to pH 3.5-6.5 and **lyophilizing**. For example, 4.5 g LH-RH, to 2 g citric acid [77-92-9] and 20 g mannitol (carrier) were dissolved

in 900 mL H2O for injection, dild. to 1 L, and adjusted to pH 3.5-4.5 with 1N NaOH. The soln. was sterilized by filtration, divided into 1 mL aliquots, and lyophilized.

=> s cetorelix and lyophili?

L16 22 CETRORELIX AND LYOPHILI?

=> dup rem l16

PROCESSING COMPLETED FOR L16

L17 19 DUP REM L16 (3 DUPLICATES REMOVED)

=> d bib ab 1-19

L17 ANSWER 1 OF 19 USPATFULL DUPLICATE 1
AN 2001:14464 USPATFULL
TI Pharmaceutical formulations for sustained drug delivery
IN Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States
(U.S. corporation)
PI US 6180608 B1 20010130
AI US 1997-988851 19971211 (8)
RLI Continuation-in-part of Ser. No. US 1996-762747, filed on 11
Dec 1996,
now patented, Pat. No. US 5968895
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner:
Delacroix-Muirheid, C.
LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe,
Maria C.
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained delivery formulations comprising a water-insoluble
complex of
a peptidic compound (e.g., a peptide, polypeptide, protein,
peptidomimetic or the like) and a carrier macromolecule are
disclosed.
The formulations of the invention allow for loading of high
concentrations of peptidic compound in a small volume and for
delivery
of a pharmaceutically active peptidic compound for prolonged
periods,
e.g., one month, after administration of the complex. The
complexes of
the invention can be milled or crushed to a fine powder. In
powdered

form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptidic compound of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L17 ANSWER 2 OF 19 USPATFULL

AN 2001:144937 USPATFULL

TI Solid matrix therapeutic compositions

IN Unger, Evan C., Tucson, AZ, United States

PA ImaRx Therapeutics, Inc. (U.S. corporation)

PI US 2001018072 A1 20010830

AI US 2001-828762 A1 20010409 (9)

RLI Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING

PRAI US 1997-46379 19970513 (60)

DT Utility

FS APPLICATION

LREP Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a

surfactant in combination with a bioactive agent. The solid porous

matrix may be prepared by combining a surfactant and a therapeutic,

together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and

processing the

emulsion by controlled drying, or controlled agitation and controlled

drying to form the solid porous matrix.

L17 ANSWER 3 OF 19 USPATFULL

AN 2001:90106 USPATFULL

TI Methods for detecting lesions in dense breast tissue using LHRH antagonists

IN Garnick, Marc B., Brookline, MA, United States

PA Praecis Pharmaceuticals Incorporated (U.S. corporation)

PI US 2001002249 A1 20010531

AI US 2001-764626 A1 20010118 (9)

RLI Continuation of Ser. No. US 1998-67327, filed on 27 Apr 1998, GRANTED,

Pat. No. US 6217844

DT Utility

FS APPLICATION

LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 687
AB Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.

L17 ANSWER 4 OF 19 USPATFULL

AN 2001:121065 USPATFULL

TI Attaching agents to tissue with transglutaminase and a transglutaminase substrate

IN Green, Howard, 82 Williston St., Brookline, MA, United States
02146

Corey, George D., 65 Harding St., Newton, MA, United States
02165

Compton, Bruce J., 30 Cottage St., Lexington, MA, United States
02173

Dijan, Philippe, 170, rue de la Convention, 75015 Paris, France

PI US 6267957 B1 20010731

AI US 1999-234358 19990120 (9)

PRAI US 1998-71908 19980120 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Naff, David M.

LREP Wolf, Greenfield & Sacks, P.C.

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1730

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, products and kits are provided for attaching agents to tissue

with a linking molecule in the presence of transglutaminase. The linking

molecule and/or agent is a substrate of transglutaminase. The agent can

be a nonprotein or an enzyme such as cholinesterase or phosphodiesterase. The transglutaminase may be exogenously added or be

endogenous in tissue. In specific embodiments, the linking molecule

contains at least two contiguous linked glutamines or at least three contiguous linked lysines. A conjugate of the agent and the linking molecule may be applied to tissue, and in the presence of transglutaminase covalently bonded to the tissue via the linking molecule. A complementary linking molecule rich in lysines may be first attached to the tissue in the presence of transglutaminase, and then covalently bonded to a glutamine-containing linking molecule of the conjugate in the presence of transglutaminase. In another embodiment, a linking molecule containing multiple glutamines is covalently bonded to tissue in the presence of transglutaminase, and an agent containing multiple lysines is covalently bonded to the linking molecule in the presence of transglutaminase. Alternatively, the linking molecule contains multiple lysines and the agent contains multiple glutamines. Two tissues can be sealed together by holding the tissues in contact with each other in the presence of transglutaminase.

L17 ANSWER 5 OF 19 USPATFULL

AN 2001:108015 USPATFULL

TI Process for the one-stage resalting and purification of oligopeptides

IN Gunther, Kurt, Staatsangehorigkeit, Germany, Federal Republic of

Kunz, Franz-Rudolf, Staatsangehorigkeit, Germany, Federal Republic of

Drauz, Karlheinz, Staatsangehorigkeit, Germany, Federal Republic of

Muller, Thomas, Staatsangehorigkeit, Germany, Federal Republic of

PA Degussa-Huls Aktiengesellschaft, Germany, Federal Republic of (non-U.S.

corporation)

PI US 6258933 B1 20010710

AI US 1999-276709 19990326 (9)

PRAI DE 1998-19813849 19980327

DT Utility

FS GRANTED

EXNAM Primary Examiner: Low, Christopher S. F.

LREP Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 507

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a process for the one-stage resalting

and purification of oligopeptides. Oligopeptides are often not formed

directly as acetates when synthesised. Acetate salts of oligopeptides are however desirable as bulk-active material for medical and formulation reasons. Processes known from the prior art have hitherto involved two separate steps or pyridine-containing solvents. The resalting and purification can be combined in one step and the use of pyridine as solvent can be avoided, if the oligopeptide in the form of its chloride salt is purified with an acetate-containing solvent by liquid chromatography methods.

L17 ANSWER 6 OF 19 USPATFULL

AN 2001:55422 USPATFULL

TI Methods for detecting lesions in dense breast tissue using LHRH antagonists

IN Garnick, Marc B., Brookline, MA, United States

PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.

corporation)

PI US 6217844 B1 20010417

AI US 1998-67327 19980427 (9)

DT Utility

FS Granted

EXNAM Primary Examiner: Jones, Dameron

LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Improved methods for detecting lesions in dense breast tissue are

disclosed. The methods of the invention generally feature administration

to a subject of an LHRH antagonist in an amount and for a period of time

sufficient to reduce the density of breast tissue prior to generating an

image of the breast tissue, for example by mammography, to detect a

lesion in the breast tissue. Packaged formulations for reducing breast

density in a subject prior to generating an image of the subject's

breast tissue, comprising an LHRH antagonist packaged with instructions

for using the LHRH antagonist to reduce breast density in a subject

prior to imaging the breast tissue, are also disclosed.

L17 ANSWER 7 OF 19 USPATFULL

AN 2001:52022 USPATFULL

TI GnRH antagonists being modified in positions 5 and 6

IN Semple, Graeme, Gothenburg, Sweden

Jiang, Guangcheng, San Diego, CA, United States
PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)
PI US 6214798 B1 20010410
WO 9846634 19981022
AI US 2000-402698 20000103 (9)
WO 1998-US7438 19980413
20000103 PCT 371 date
20000103 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1997-837042, filed on 11
Apr 1997,
now patented, Pat. No. US 5925730
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner:
Delacroix-Muirheid, C.
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptides are provided which have improved duration of GnRH
antagonistic
properties. These antagonists may be used to regulate
fertility and to
treat steroid-dependent tumors and for other short-term and
long-term
treatment indications. These antagonists have a derivative of
aminoPhe
or its equivalent in the 5- or the 5- and 6-positions. This
derivative
is modified so as to contain a carbamoyl group or heterocycle,
including
a urea moiety, in its side chain. Decapeptides having the
formula:

Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-hydroorotyl)-D-4Amf(Q.sub.2)-Leu-
Lys(isopropyl)-Pro-Xaa.sub.10,

wherein Q.sub.2 is Cbm or MeCbm and Xaa.sub.10 is D-Ala-ol or
Ala-ol are
particularly effective and continue to exhibit very substantial
suppression of LH secretion at 96 hours following injection.

L17 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:764638 CAPLUS

TI Low-temperature micronization of a peptide drug in fluid
propellant: case

study **cetrorelix**

AU Lizio, Rosario; Damm, Michael; Sarlikiotis, Antonio W.; Bauer,
Horst H.;

Lehr, Claus-Michael

CS Dep. Biopharmaceutics and Pharmaceutical Technol., Saarland
Univ.,

Saarbrücken, 66123, Germany

SO AAPS PharmSciTech (2001), 2(3), No pp. given

CODEN: AAPHFZ; ISSN: 1522-1059

URL:

<http://www.aapspharmaceutica.com/scientificjournals/volume2issue3/049>

/manuscript.pdf
PB American Association of Pharmaceutical Scientists
DT Journal; (online computer file)
LA English
AB Aim of this study was to elaborate an efficient method for the micronization of the decapeptide **cetrorelix** (a GnRH-antagonist), in order to obtain a microsuspension as basis for other pharmaceutical prepns., such as e.g. inhalation aerosols. A modified pearl-mill coupled with a cryostat was used for the micronization of **cetrorelix** in fluid propellant and operated under different conditions. The obtained **cetrorelix** suspensions were analyzed for particle size distribution, purity of **cetrorelix**, and for metal contamination through abrasion from parts of the mill. The method allowed an effective micronization of **cetrorelix**. The mean particle size of the initial **cetrorelix lyophilizate** bulk were was reduced from 52.5 μm (Vol. Mean Diam., VMD) down to 14.9, 6.1 and 3.1 μm , resp., resp. The HPLC anal. of all **cetrorelix** suspensions after micronization did not show signs of decompn. as compared to the initial product. The elementary anal. of the suspensions performed by inductively coupled plasma mass spectrometry revealed a negligible amt. of contaminants in the suspension (Zr = max. 0.6 ppm; Fe, Cr, Ni, Ba, below limit of quantification, i.e. < 0.14 ppm). The only appreciable contaminant, Aluminum (Al = 1.1 ppm), was derived from the mech. capping of aluminum canisters prior to anal. The Zr detn. in the suspension of 0.6 ppm, is still considered to be negligible as compared to the legally tolerated limit of air contamination. By low-temp. micronization in fluid propellant, fine drug suspensions of **cetrorelix** for pMDIs can be directly manufd. in one-step procedure without destruction of the peptide structure and without appreciable product contamination.

L17 ANSWER 9 OF 19 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2
AN 2000:477618 BIOSIS
DN PREV200000477618
TI Process for the preparation of immobilized and activity-stabilized complexes of LHRH antagonists.
AU Engel, Jurgen (1); Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter;
Naumann, Wolfgang; Murgas, Sandra
CS (1) Alzenau Germany
ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany
PI US 6054555 April 25, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Apr. 25, 2000) Vol. 1233, No. 4, pp. No pagination. e-file.
ISSN: 0098-1133.

DT Patent
LA English
AB In this invention, a release-delaying system is to be developed for LHRH antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2 O5 in vacuo. If complexes having a defined composition are to be obtained, **lyophilization** proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L17 ANSWER 10 OF 19 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 3
AN 2000:355483 BIOSIS

DN PREV200000355483

TI Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation.

AU Engel, Jurgen (1); Deger, Wolfgang; Reissmann, Thomas; Losse, Gunter;

Naumann, Wolfgang; Murgas, Sandr

CS (1) Alzenau Germany

ASSIGNEE: Asta Medica Aktiengesellschaft, Dresden, Germany

PI US 6022860 February 08, 2000

SO Official Gazette of the United States Patent and Trademark Office Patents,

(Feb. 8, 2000) Vol. 1231, No. 2, pp. No pagination. e-file.

ISSN: 0098-1133.

DT Patent

LA English

AB In this invention, a release-delaying system is to be developed for LHRH

antagonists, in particular for **cetrorelix**, which allows the active compound to be released in a controlled manner over several weeks

by complexation with suitable biophilic carriers. The acidic polyamino acids polyglutamic acid and polyaspartic acid were selected for complexation with **cetrorelix**. The **cetrorelix** polyamino acid complexes are prepared from aqueous solutions by combination of the solutions and precipitation of the complexes, which are subsequently centrifuged off and dried over P2 O5 in vacuo. If complexes having a defined composition are to be obtained, **lyophilization** proves to be a suitable method. The **cetrorelix**-carboxylic acid complexes were also prepared from the aqueous solutions. In the random liberation system, the acidic polyamino acids poly-Glu and poly-Asp showed good release-delaying properties as a function of the hydrophobicity and the molecular mass of the polyamino acid. In animal experiments, it was possible to confirm the activity of the **cetrorelix**-polyamino acid complexes as a depot system in principle. It is thus possible by complexation of **cetrorelix** with polyamino acids to achieve testosterone suppression in male rats over 600 hours. The release of active compound here can be controlled by the nature and the molecular mass of the polymers.

L17 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:573692 CAPLUS

DN 133:182987

TI Sustained release salts of pharmaceutically active peptides and their

production
IN Bauer, Horst; Deger, Wolfgang; Sarlikiotis, Werner; Damm, Michael
PA Asta Medica A.-G., Germany
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047234	A1	20000817	WO 2000-EP697	20000129
	W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRAI US 1999-119076 P 19990208

AB Substained delivery pharmaceutical compns. comprise a water insol. salt of

a pharmaceutically active ionic peptide and a counterionic carrier

macromol. The peptide may be an LHRH antagonist such as **cetrorelix** and the macromol. may be an anionic polysaccharide such as CM-cellulose. The salt is prepd. using ion exchangers to sep. remove the counterions from the peptide and the carrier macromol. thereby forming free peptide/macromol. ions. These free peptide and macromol. ions are then combined to form the water insol. peptide-macromol. salt. A **lyophilizate** of **cetrorelix**-CM-cellulose salt was prepd.

RE.CNT 6

RE

- (1) Asta Medica Ag; WO 9842381 A 1998 CAPLUS
- (2) Kamei, S; WO 9832423 A 1998 CAPLUS
- (3) Klokke-Bethke, K; US 5773032 A 1998 CAPLUS
- (4) Molineaux, C; WO 9825642 A 1998 CAPLUS
- (5) Nestor, J; US 4581169 A 1986 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 19 USPATFULL

AN 1999:128511 USPATFULL

TI Pharmaceutical formulations for sustained drug delivery

IN Gefter, Malcolm L., Lincoln, MA, United States

Barker, Nicholas, Southborough, MA, United States

Musso, Gary, Hopkinton, MA, United States

Molineaux, Christopher J., Brookline, MA, United States

PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States
(U.S.

corporation)

PI US 5968895 19991019

AI US 1996-762747 19961211 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Richter, Johann; Assistant Examiner:
Delacroix-Muirheid, C.

LREP Lahive & Cockfield, LLP, Mandragouras, Amy E., DeConti, Giulio
A.

CLMN Number of Claims: 32

ECL Exemplary Claim: 10

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 775

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained delivery formulations comprising a water-insoluble complex of

a peptide and a carrier macromolecule are disclosed. The formulations of

the invention allow for loading of high concentrations of peptide in a

small volume and for delivery of a pharmaceutically active peptide for

prolonged periods, e.g., one month, after administration of the complex.

The complexes of the invention can be milled or crushed to a fine

powder. In powdered form, the complexes form stable aqueous suspensions

and dispersions, suitable for injection. In a preferred embodiment, the

peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.

L17 ANSWER 13 OF 19 USPATFULL

AN 1999:99641 USPATFULL

TI LH-RH antagonists having improved action

IN Kutscher, Bernhard, Maintal, Germany, Federal Republic of
Bernd, Michael, Frankfurt, Germany, Federal Republic of
Beckers, Thomas, Frankfurt, Germany, Federal Republic of
Klenner, Thomas, Ingelheim, Germany, Federal Republic of
Emig, Peter-Paul, Bruchkobel, Germany, Federal Republic of
Charpentier, Patricia-Marie, Maintal, Germany, Federal

Republic of

PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal

Republic of

(non-U.S. corporation)

PI US 5942493 19990824

AI US 1998-87274 19980528 (9)

RLI Continuation-in-part of Ser. No. WO 1996-DE2171, filed on 14
Nov 1996

PRAI DE 1995-19544212 19951128

DT Utility

FS Granted

EXNAM Primary Examiner: Davenport, Avis M.

LREP Pillsbury Madison & Sutro LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1219

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New LH-RH antagonists are disclosed, in particular
peptidomimetics and

peptides modified in a side chain, their salts with
pharmaceutically

acceptable acids and a process for preparing these LH-RH
antagonists and

their salts. The disclosed peptides represent analogues of the
luteinising hormone releasing hormone (LH-RH). The disclosed
compounds

have a high antagonistic power and are free of undesirable
side effects,

in particular edematogenic effects.

L17 ANSWER 14 OF 19 USPATFULL

AN 1999:81921 USPATFULL

TI GnRH antagonists

IN Semple, Graeme, Hampshire, United Kingdom

Jiang, Guangcheng, San Diego, CA, United States

PA Ferring BV, Hoofddorp, Netherlands (non-U.S. corporation)

PI US 5925730 19990720

AI US 1997-837042 19970411 (8)

DT Utility

tumors and for other short-term and long-term treatment indications. One particularly effective peptide, a decapeptide analog of the GnRH antagonist Acyline, has the formula: Ac-D-2Nal-D-4Cpa-D-Dpr(methylcarbamoyl)-Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2. It continues to exhibit very substantial suppression of LH secretion at 96 hours following injection. Other economically attractive and pharmacologically effective analogs have the formulas:

Ac-D-2Nal-D-4Cpa-Xaa.sub.3
 -Ser-4Aph(acetyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2 ; and
 Ac-D-2Nal-D-4Cpa-Xaa.sub.3

-Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopropyl)-Pro-D-Ala-NH.sub.2, wherein Xaa.sub.3 is D-Gln or Gln.

L17 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:672495 CAPLUS
 DN 129:293891
 TI Immobilized activity-stabilized LHRH antagonist complexes and their

production
 IN Engel, Juergen; Deger, Wolfgang; Reissmann, Thomas; Losse, Guenter;

Naumann, Wolfgang; Murgas, Sandra
 PA Asta Medica Aktiengesellschaft, Germany
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2

DT Patent
 LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842381	A1	19981001	WO 1998-EP1398	19980311
TR, UA	W: AU, BR, CA, CN, CZ, HU, IL, JP, MX, NO, NZ, PL, RU, SK,				
NL, PT, SE	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,				
	DE 19712718	A1	19981001	DE 1997-19712718	19970326
	DE 19712718	C2	19990923		
	AU 9869207	A1	19981020	AU 1998-69207	19980311
	BR 9807887	A	20000222	BR 1998-7887	19980311
	EP 981377	A1	20000301	EP 1998-914877	19980311
MC, PT,	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,				
	IE, FI				
	JP 2001520662	T2	20011030	JP 1998-544811	19980311
	US 6022860	A	20000208	US 1998-48244	19980326
	NO 9904665	A	19990924	NO 1999-4665	19990924
	US 6054555	A	20000425	US 1999-422990	19991022
PRAI	DE 1997-19712718	A	19970326		
	WO 1998-EP1398	W	19980311		
	US 1998-48244	A3	19980326		

AB LHRH antagonists, esp. **cetrorelix**, are complexed with suitable biophilic carriers to enable sustained, targeted release of the active substance over a period of several weeks. The acidic polyamino acids, polyaspartic and polyglutamic acids, are selected for complexation with **cetrorelix**. The **cetrorelix**/polyamino acid complexes are produced from aq. solns. by combining the solns. and pptg. the complexes which are subsequently centrifuged off and vacuum dried over P2O5, preferably by lyophilization. These acidic polyamino acids display good sustained-release properties in a static liberation system depending on the hydrophobicity and molar mass of the polyamino acids. Animal testing demonstrated the efficacy of the **cetrorelix**/polyamino acid complexes as a depot system. By complexation of **cetrorelix** with polyamino acids, testosterone suppression can be achieved in male rats over a period of 600 h. Active substance release can thus be controlled according to polymer type and molar mass.

L17 ANSWER 17 OF 19 USPATFULL

AN 97:78416 USPATFULL

TI Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases

IN Engel, Jurgen, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of

PA ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of
(non-U.S. corporation)

PI US 5663145 19970902

AI US 1994-354838 19941208 (8)

PRAI DE 1993-4342091 19931209

DT Utility

FS Granted

EXNAM Primary Examiner: Russel, Jeffrey E.

LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro
LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 7

DRWN No Drawings

LN.CNT 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB For application during the treatment of benign and malignant tumour

diseases, the product according to the invention containing the initial

dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.

L17 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1995:677500 CAPLUS

DN 123:65874

TI Products for the application of high initial doses of **cetrorelix** and preparation of a combined package for use in treating diseases

IN Engel, Juergen; Hilgard, Peter; Reissmann, Thomas

PA Asta Medica A.-G., Germany

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 657170	A1	19950614	EP 1994-118466	19941124
	EP 657170	B1	20000315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 190495	E	20000415	AT 1994-118466	19941124
	ES 2145803	T3	20000716	ES 1994-118466	19941124
	CA 2137595	AA	19950610	CA 1994-2137595	19941208
	US 5663145	A	19970902	US 1994-354838	19941208
	JP 07194670	A2	19950801	JP 1994-306475	19941209

PRAI DE 1993-4342091 A 19931209

AB A pharmaceutical product, esp. suitable for treatment of hormone-dependent

tumors, comprises a package of containers, of which .gtoreq.1 containers

each contain an initial dose of drug and .gtoreq.1 addnl. containers

contain a maintenance dose. The maintenance doses may be in delayed-release form. Thus, a 1-mo supply of **cetrorelix** comprised .gtoreq.1 container contg. an initial dose (1-60 mg) **lyophilized cetrorelix acetate** and .ltoreq.30 addnl. containers contg. a maintenance dose (0.1-10 mg) **lyophilized cetrorelix acetate**.

L17 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:587330 CAPLUS

DN 121:187330

TI Preparation of a **cetrorelix lyophilized** composition

IN Engel, Juergen; Sauerbier, Dieter; Wichert, Burkhard; Reissmann, Thomas

PA Asta Medica AG, Germany

SO Eur. Pat. Appl., 5 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 611572	A2	19940824	EP 1994-101672	19940204
	EP 611572	A3	19950111		
	EP 611572	B1	20000607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	DE 4305225	A1	19940825	DE 1993-4305225	19930219
	TW 387812	B	20000421	TW 1994-83100769	19940131
	EP 947200	A2	19991006	EP 1999-102340	19940204

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT, IE

AT 193653	E	20000615	AT 1994-101672	19940204
ES 2148247	T3	20001016	ES 1994-101672	19940204
CZ 284314	B6	19981014	CZ 1994-312	19940214
CZ 285768	B6	19991117	CZ 1998-974	19940214
AU 9455235	A1	19940825	AU 1994-55235	19940217
AU 671881	B2	19960912		
JP 06271476	A2	19940927	JP 1994-20532	19940217
PL 177177	B1	19991029	PL 1994-302266	19940217
CA 2115943	AA	19940820	CA 1994-2115943	19940218
FI 9400779	A	19940820	FI 1994-779	19940218
NO 9400564	A	19940822	NO 1994-564	19940218
ZA 9401136	A	19940829	ZA 1994-1136	19940218
BR 9400617	A	19940927	BR 1994-617	19940218
HU 67117	A2	19950228	HU 1994-481	19940218
HU 218281	B	20000728		
CN 1112019	A	19951122	CN 1994-101378	19940218
RU 2145234	C1	20000210	RU 1994-5001	19940218
PRAI DE 1993-4305225	A	19930219		
EP 1994-101672	A3	19940204		

AB A **lyophilizate** of a peptide with 3-15 amino acid residues (e.g. **cetrorelix**) and .gtoreq.1 optional matrix materials (e.g. mannitol) is prepd. by dissolving in 100-10,000 wt. parts AcOH, dilg. with water, and **lyophilizing** the resulting soln. The **lyophilizate** is useful for prepn. of a medication for treatment of female infertility and protection of the gonads from the follicular hyperstimulation seen with other infertility treatments.